Insider Buying: Septerna, Inc. (NASDAQ:SEPN) CFO Acquires 6,282 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie bought 6,282 shares of the firm’s stock in a transaction on Tuesday, February 25th. The stock was acquired at an average price of $5.59 per share, for a total transaction of $35,116.38. Following the completion of the purchase, the chief financial officer now directly owns 36,282 shares in the company, valued at approximately $202,816.38. The trade was a 20.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Septerna Stock Performance

Shares of SEPN stock opened at $6.47 on Friday. Septerna, Inc. has a fifty-two week low of $4.17 and a fifty-two week high of $28.99. The stock has a 50 day simple moving average of $16.08.

Institutional Investors Weigh In On Septerna

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC bought a new stake in shares of Septerna in the 4th quarter worth approximately $25,000. New York State Common Retirement Fund bought a new stake in shares of Septerna in the 4th quarter worth approximately $32,000. Legal & General Group Plc bought a new stake in shares of Septerna in the 4th quarter worth approximately $42,000. Summit Investment Advisors Inc. bought a new stake in shares of Septerna during the fourth quarter valued at approximately $45,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Septerna during the fourth quarter valued at approximately $52,000.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on SEPN shares. JPMorgan Chase & Co. started coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $50.00 target price on shares of Septerna in a research note on Tuesday, February 11th. Wells Fargo & Company lowered Septerna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $43.00 to $14.00 in a research report on Tuesday, February 18th. Finally, TD Cowen initiated coverage on Septerna in a research report on Tuesday, November 19th. They set a “buy” rating on the stock.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.